Silverarc Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Silverarc Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,344	Closed	-$3.43M	–	78
2025 Q1	$3.43M	Buy	+10,344	New	+$3.4M	0.7%	36
2023 Q2	–	Sell	-10,000	Closed	-$2.42M	–	92
2023 Q1	$2.42M	Sell	10,000 -39,898	-80%	-$10.9M	1%	40
2022 Q4	$14.5M	Buy	+49,898	New	+$4.88M	4.14%	2
2021 Q3	–	Sell	-2,480	Closed	-$242K	–	95
2021 Q2	$242K	Buy	+2,480	New	+$294K	0.11%	89

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Silverarc Capital Management's MDGL Position: Q2 2025 in Review

Silverarc Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 10,344 shares — an estimated $3.43M sold.

Silverarc Capital Management first reported a position in MDGL in Q2 2021 and held it in 4 quarters. The position peaked at $14.5M in Q4 2022. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

Silverarc Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Silverarc Capital Management sold 10,344 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $3.43M.
Silverarc Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Silverarc Capital Management's Madrigal Pharmaceuticals position peaked at $14.5M in Q4 2022.
305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.